Article

ASCO Picks Top Advances in Cancer Treatment

Advances in screening and prevention, treatments for refractory cancers, and ways to reduce cancer recurrence were part and parcel of the progress made against the disease in 2011, according to the American Society of Clinical Oncology.

A reduction in lung cancer death rates of 20% for high-risk individuals following low-dose computed tomography scanning was one of the more important screening advances of the past year. This was the first successful trial over many decades of trying to find a screening regimen for these patients, reported Steven I. Benowitz, MA, from ASCO, and colleagues.

Among the advances in new drug approvals was the clearance of crizotinib (Xalkori) for use in lung cancer patients whose tumor has a specific alteration in the anaplastic lymphoma kinase gene, the authors noted online in the Journal of Clinical Oncology. The 31% improved survival over two years was heralded as another example of successfully personalizing the treatment of cancers.

Read more at: http://www.medpagetoday.com/HematologyOncology/ProstateCancer/30384?utm_medium=email&utm_campaign=DailyHeadlines&utm_source=WC&email=nyanovsky@ajmc.com&eun=g435943d0r&userid=435943&mu_id=

Source: Medpage Today

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Eric Lander, MD
Eric Lander, MD
David Awad, PharmD, BCOP
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo